24.08.2026
The Hidden Challenges Of ADC Manufacturing - And How To Overcome Them
The oncology pipeline is transforming. More than 100 ADCs are currently in clinical development. These therapies offer unprecedented specificity—but they also introduce manufacturing requirements that differ fundamentally from conventional biologics.
For many developers, the biggest operational question becomes: “Can my CDMO truly handle this type of molecule?”
Based on our experience at medac CDMO, the answer depends not on general biologics capability, but on deep specialization. By offering insight into these operational realities, our intent is not merely to describe our capabilities but help to make informed decisions in an increasingly complex outsourcing landscape.
The Growing Complexity of Oncology Therapies
The oncology landscape is expanding rapidly as diagnostic capabilities improve and populations age. Therapies such as antibody–drug conjugates (ADCs), monoclonal antibodies, and mRNA-based immunotherapies are becoming central to modern cancer treatment strategies. Their promise lies in the ability to target specific disease mechanisms with greater precision, but this same sophistication also introduces manufacturing challenges that traditional biologics platforms cannot easily address.
ADCs illustrate this shift particularly well. As hybrids of highly potent small-molecule payloads and sensitive monoclonal antibodies, they require careful management of potency, stability, sterility, and molecular integrity. Even small variations in pressure, temperature, shear stress, or handling conditions can significantly affect performance. For many developers, the question is no longer whether these modalities will become mainstream but whether their manufacturing partners truly understand the operational complexities required to bring them safely to clinic.
The Role of Single-Use Systems in Mitigating Manufacturing Risk
The transition to single-use systems (SUS) has moved from an industry trend to a manufacturing necessity, particularly for high-potency and high-sensitivity compounds. At medac CDMO, SUS are integrated throughout the formulation process to provide controlled and segregated environments for cytostatic and biologic manufacturing. The use of SUS reduces cross-contamination risk, eliminates the burdens of cleaning validation, protects operators from hazardous materials, and supports a high degree of customization in tubing, bag formats, and aseptic connectors.
Equally important is the precision enabled by disposable sensors and monitoring devices that operate within the SUS environment. For molecules that are highly sensitive to variations in temperature, oxygen levels, or pressure, this monitoring capability provides an essential safeguard. SUS technology therefore becomes more than an equipment choice; it functions as a risk-control strategy that supports consistency, product safety, and compliance with stringent GMP requirements.
Filtration as a Critical Control Point for ADC Stability
Among all steps in ADC manufacturing, sterile filtration is often the most underestimated. In practice, filtration presents a significant technical challenge due to the viscosity and sensitivity of many ADC formulations. At medac CDMO, filtration is conducted within aseptically assembled SUS configurations using dual in-line PVDF filters, ensuring the required sterility while protecting the structure of the antibody.
Filtration performance depends heavily on carefully controlled flow rates and pressure conditions. Excessive pressure or shear can cause aggregation or destabilization, while insufficient flow can compromise throughput. In-line filter integrity testing, performed directly within the SUS setup, allows both pre- and post-use verification without exposing the product to environmental risk. This capability is particularly important for ADCs, where product loss is extremely costly and batch reproducibility is critical for clinical supply.
Aseptic Filling Designed for Fragile and High-Potency Molecules
Following filtration, ADCs are transferred into an intermediate vessel within an isolator to maintain aseptic continuity between process steps. Filling operations must be tailored to the sensitivity of these formulations.
Accurate dosing becomes essential when working with small-volume, high-value oncology products. Each vial is weighed in-line to ensure it meets defined specifications, and filling parameters are adapted to the degradation profile of the molecule. This nuanced control is especially important in clinical supply, where even minor inconsistencies can affect trial outcomes or impede regulatory review.
Integrated Lyophilization to Enhance Stability and Supply Reliability
Lyophilization plays an increasingly important role in the stability and distribution of next-generation oncology therapies. At medac CDMO, the lyophilizer is directly integrated into the isolator-based filling line, ensuring that the drug product is never exposed to non-aseptic conditions from filling through stoppering, drying, and crimping. This fully contained process significantly lowers contamination risk.
Lyophilization cycles are developed according to the specific physicochemical properties of the molecule, helping to preserve structural integrity while enhancing shelf life. The integration of lyophilization into the isolator allows seamless transfer between steps, avoids unnecessary handling, and improves overall supply-chain robustness.
For many developers, the biggest operational question becomes: “Can my CDMO truly handle this type of molecule?”
Based on our experience at medac CDMO, the answer depends not on general biologics capability, but on deep specialization. By offering insight into these operational realities, our intent is not merely to describe our capabilities but help to make informed decisions in an increasingly complex outsourcing landscape.
The Growing Complexity of Oncology Therapies
The oncology landscape is expanding rapidly as diagnostic capabilities improve and populations age. Therapies such as antibody–drug conjugates (ADCs), monoclonal antibodies, and mRNA-based immunotherapies are becoming central to modern cancer treatment strategies. Their promise lies in the ability to target specific disease mechanisms with greater precision, but this same sophistication also introduces manufacturing challenges that traditional biologics platforms cannot easily address.
ADCs illustrate this shift particularly well. As hybrids of highly potent small-molecule payloads and sensitive monoclonal antibodies, they require careful management of potency, stability, sterility, and molecular integrity. Even small variations in pressure, temperature, shear stress, or handling conditions can significantly affect performance. For many developers, the question is no longer whether these modalities will become mainstream but whether their manufacturing partners truly understand the operational complexities required to bring them safely to clinic.
The Role of Single-Use Systems in Mitigating Manufacturing Risk
The transition to single-use systems (SUS) has moved from an industry trend to a manufacturing necessity, particularly for high-potency and high-sensitivity compounds. At medac CDMO, SUS are integrated throughout the formulation process to provide controlled and segregated environments for cytostatic and biologic manufacturing. The use of SUS reduces cross-contamination risk, eliminates the burdens of cleaning validation, protects operators from hazardous materials, and supports a high degree of customization in tubing, bag formats, and aseptic connectors.
Equally important is the precision enabled by disposable sensors and monitoring devices that operate within the SUS environment. For molecules that are highly sensitive to variations in temperature, oxygen levels, or pressure, this monitoring capability provides an essential safeguard. SUS technology therefore becomes more than an equipment choice; it functions as a risk-control strategy that supports consistency, product safety, and compliance with stringent GMP requirements.
Filtration as a Critical Control Point for ADC Stability
Among all steps in ADC manufacturing, sterile filtration is often the most underestimated. In practice, filtration presents a significant technical challenge due to the viscosity and sensitivity of many ADC formulations. At medac CDMO, filtration is conducted within aseptically assembled SUS configurations using dual in-line PVDF filters, ensuring the required sterility while protecting the structure of the antibody.
Filtration performance depends heavily on carefully controlled flow rates and pressure conditions. Excessive pressure or shear can cause aggregation or destabilization, while insufficient flow can compromise throughput. In-line filter integrity testing, performed directly within the SUS setup, allows both pre- and post-use verification without exposing the product to environmental risk. This capability is particularly important for ADCs, where product loss is extremely costly and batch reproducibility is critical for clinical supply.
Aseptic Filling Designed for Fragile and High-Potency Molecules
Following filtration, ADCs are transferred into an intermediate vessel within an isolator to maintain aseptic continuity between process steps. Filling operations must be tailored to the sensitivity of these formulations.
Accurate dosing becomes essential when working with small-volume, high-value oncology products. Each vial is weighed in-line to ensure it meets defined specifications, and filling parameters are adapted to the degradation profile of the molecule. This nuanced control is especially important in clinical supply, where even minor inconsistencies can affect trial outcomes or impede regulatory review.
Integrated Lyophilization to Enhance Stability and Supply Reliability
Lyophilization plays an increasingly important role in the stability and distribution of next-generation oncology therapies. At medac CDMO, the lyophilizer is directly integrated into the isolator-based filling line, ensuring that the drug product is never exposed to non-aseptic conditions from filling through stoppering, drying, and crimping. This fully contained process significantly lowers contamination risk.
Lyophilization cycles are developed according to the specific physicochemical properties of the molecule, helping to preserve structural integrity while enhancing shelf life. The integration of lyophilization into the isolator allows seamless transfer between steps, avoids unnecessary handling, and improves overall supply-chain robustness.
